Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Core Viewpoint - The market anticipates a year-over-year decline in Supernus Pharmaceuticals' earnings despite an increase in revenues when the company reports its quarterly results for the period ending September 2025 [1][3]. Earnings Expectations - Supernus is expected to report earnings of $0.47 per share, reflecting a significant year-over-year decrease of 55.7%. Revenue is projected to be $182.06 million, which is a 3.6% increase compared to the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 14.29% higher in the last 30 days, indicating a reassessment by analysts of their initial estimates [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%. This suggests no recent differing analyst views from the consensus [12]. Historical Performance - In the last reported quarter, Supernus exceeded the expected earnings of $0.47 per share by delivering $0.91, resulting in a surprise of +93.62%. The company has beaten consensus EPS estimates in all of the last four quarters [13][14]. Investment Considerations - Despite the positive historical performance, Supernus does not appear to be a strong candidate for an earnings beat this time. Investors are advised to consider other factors beyond earnings results when making investment decisions [15][17].